-

Eurofins Medical Device Services Launches first GMP PFAS Screening and Testing Solutions for Medical Devices

LANCASTER, Pa.--(BUSINESS WIRE)--Eurofins Medical Device Services North America, part of a global network of over 20 medical device testing laboratories and a leading medical device solutions partner, recently launched a GMP PFAS testing and screening solution, the first developed and commercialized for the medical device industry. This offering provides insights to medical device manufacturers as they navigate the complex and evolving global regulations surrounding PFAS, ultimately contributing to medical device and patient safety.

Per- and polyfluoroalkyl substances, or PFAS, are a group of more than twenty thousand chemical compounds which are highly resistant to degradation and have been found to pose potential threats to human health and the environment. Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates and avoid future shutdowns, recalls, and liability issues, while further supporting their sustainability goals.

Eurofins Medical Device Services North America’s GMP PFAS testing and screening solution includes:

  • Combustion Ion Chromatography (CIC) for total organic fluorine screening in solids, liquids, and gases, to provide an initial assessment of PFAS levels.
  • Process mapping and supply chain audits, to identify contamination pathways.
  • Solvent extraction and direct combustion for flexible sample formats.
  • Extractables & Leachables (E&L) testing, toxicological risk assessments, and aging studies.
  • Stability and forced degradation studies, to identify PFAS breakdown products.

Eurofins Medical Device Services North America operates under ISO 17025 accreditation standards, and applies GMP best practices, ensuring sensitivity, specificity, and reproducibility even at trace levels.

Learn more at https://www.eurofins.com/medical-device/

About Eurofins Medical Device Services

Eurofins Medical Device Services offers comprehensive testing, consulting, and regulatory support for Class I, II, and III medical devices—including implants, instruments, single-use and combination products, and wearables.

With more than 40 years of experience, our global network of medical device testing laboratories and consultants provide strategic guidance from biological evaluation plans through commercialization, and specialize in international regulatory requirements, scientific trends, and tailored testing strategies.

Committed to global standards, Eurofins Medical Device Services designs and executes testing plans aligned with ISO, ASTM, ANSI, and AAMI standards, as well as custom methodologies. Our quality systems meet GMP and ISO 17025 requirements, helping clients accelerate market access with confidence.

Contacts

For further information:
Lisa Bamford
Medical Device Services Communications Director
Lisa.bamford@bpt.eurofinsus.com

Eurofins

BOURSE:ERF

Release Versions

Contacts

For further information:
Lisa Bamford
Medical Device Services Communications Director
Lisa.bamford@bpt.eurofinsus.com

More News From Eurofins

Eurofins MET Laboratories Opens New Safety, EMC, Wireless, and Renewable Energy Laboratory in the Boston Tech Corridor

BOSTON--(BUSINESS WIRE)--Eurofins MET Laboratories, part of the Eurofins Electrical & Electronics global network, announces the opening of its new state-of-the-art 60,000-square-foot testing laboratory in Littleton, Massachusetts – a prime location in the Boston innovation corridor. Positioned at the epicenter of New England's med-tech, wireless innovation, clean energy, and advanced electronics ecosystem, the capabilities of this laboratory further position Eurofins MET Laboratories as the...

Eurofins Scientific SE: Weekly Report on Share Repurchases from 26th January to 30th January 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 26/01/2026 FR0014000MR3 5 000 70.7336 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 27/01/2026 FR0014000MR3 5 000 70.9680 XPAR EUROFINS SCIENTIFIC 529900JEHFM47...

Eurofins Delivers FY 2025 Objectives with a 24% EPS Growth, Accelerating Organic Revenue Growth, Margin Expansion, and Higher Free Cash Flow and Confirms Its 2027 Objectives

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF) pre-publishes below its preliminary unaudited consolidated financial results for the year ending 31 December 2025, as described in the first paragraphA of the Business Review section of this press release. Financial highlights in FY 2025 Basic EPS8 grew 24% to €2.31 in 2025 vs €1.87 in 2024, driven by a strong operating performance and starting to reap the benefits from Eurofins five-year investment programme in its hub and spok...
Back to Newsroom